Reese, Imke
Ahrens, Birgit
Ballmer-Weber, Barbara
Beyer, Kirsten
Blümchen, Katharina
Doelle-Birke, Sabine
Heratizadeh, Annice
Kleine-Tebbe, Jörg
Lange, Lars
Lau, Susanne
Lepp, Ute
Mahler, Vera
Schäfer, Christiane
Schnadt, Sabine
Szepfalusi, Zsolt
Wassmann-Otto, Anja
Werfel, Thomas
Worm, Margitta
Funding for this research was provided by:
Charité
Article History
Received: 15 June 2020
Accepted: 25 June 2020
First Online: 1 September 2020
Conflict of interest
: B. Ahrens and V. Mahler state that the content and opinions expressed in this position paper reflect the personal expert opinions of the authors and should not be interpreted or cited as if they had been made on behalf of the relevant higher national federal authorities, the European Medicines Agency, or one of its committees or working groups, or reflects their position. K. Beyer declares having received grants and honoraria from Aimmune, DBV, Infectopharm, and Mylan, outside the present work. K. Blümchen declares having received grants and/or honoraria from Novartis, HAL Allergy, ThermoFisher, Bencard Allergie, Allergopharma, ALK, DBV technologies, Aimmune Therapeutics, Nestle, and Nutricia, outside the present work. A. Heratizadeh declares having received honoraria from LEO Pharma, Novartis, Pierre Fabre, Sanofi-Genzyme, Beiersdorf, Hans Karrer, Nutricia, Meda, and Lilly, as well as grants from Janssen, outside the present work. S. Lau declares having received honoraria from DBV, Sanofi-Aventis, Allergopharma, and ALK, outside the present work. M. Worm declares having received advisory board and lecture honoraria from Allergopharma GmbH & Co. KG, ALK-Abelló Arzneimittel GmbH, Mylan Germany GmbH, Leo Pharma GmbH, Sanofi-Aventis Deutschland GmbH, Regeneron Pharmaceuticals, DBV Technologies S.A, Stallergenes GmbH, HAL Allergie GmbH, Bencard Allergie GmbH, Aimmune Therapeutics UK Limited, Actelion Pharmaceuticals Deutschland GmbH, Novartis AG, Biotest AG, AbbVie Deutschland GmbH & Co. KG, and Lilly Deutschland GmbH, outside the present work. B. Ballmer-Weber reports personal fees from ThermoFisher Scientific, personal fees from Stallergenes, personal fees from Novartis, outside the submitted work. I. Reese, S. Doelle-Birke, J. Kleine-Tebbe, L. Lange, U. Lepp, C. Schäfer, S. Schnadt, Z. Szepfalusi, A. Wassmann-Otto and T. Werfel declare that they have no competing interests.